Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Bureau Veritas SA    BVI   FR0006174348


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eurofins to slow pace of M&A, expand in emerging markets

share with twitter share with LinkedIn share with facebook
share via e-mail
07/08/2019 | 12:52pm EDT
FILE PHOTO: Different meat samples in test tubes are seen in food control laboratory institute Eurofins in Ebersberg

PARIS (Reuters) - Laboratory-testing company Eurofins Scientific plans to slow its frantic dealmaking pace in the next two years while also expanding in emerging markets to maintain double-digit sales growth over the next decade, its finance director said.

The French-listed company, a world leader in food, pharma and environmental laboratory testing, almost doubled its revenues between 2015 and 2018 by buying dozens of companies. It now employs 45,000 staff in 47 countries.

Eurofins develops and sells tests for the pharmaceutical, food and environmental sectors to assess the safety, composition or purity of goods. It competes with companies including Evotec, Bureau Veritas and Intertek in a fragmented, multibillion dollar market.

Eurofins' shares are up 20% year-to-date.

Hugues Vaussy told Reuters that rising demand for testing globally would underpin growth, supported by greater consumer and environmental awareness, while education and purchasing power levels were rising in emerging economies.

"As of today, we make around 85% of our business in Europe and North America. Looking forward, having a balanced geographic mix between these two regions and the rest of the world would make much more sense," Vaussy said.

Founded by a doctor, Gilles Martin, who purchased the rights of a food and beverages-testing technology developed by the University of Nantes, the company has grown from a single laboratory in 1987 to more than 800 last year.

Much of its 2018 sales growth came from some 50 bolt-on acquisitions. Revenues last year came in at 3.78 billion euros ($4.24 billion), up 27.2%, while net profit rose 3.3% to 224 million euros.

Eurofins Scientific is aiming for sales of 5 billion euros in 2020 and Vaussy said the group believed it was possible to maintain an annual sales growth at 10% over the next 10 years.

"Demand is on the rise with consumer awareness increasing everywhere, better education and stronger purchasing power in many countries," Vaussy said.

But he said investors should expect a slower merger and acquisitions pace over the next two years as the group integrates recently purchased assets.

Vaussy said the ransomware computer virus, which caused disruption to its IT systems in several countries, was likely to have affected sales in the second quarter. But he said it was too soon to project the extent of the impact of the cyber attack.

"We are undertaking a laboratory by laboratory assessment of the damages," he said, adding that IT forensics experts had not found evidence of theft or transfer of confidential client data.

Vaussy declined to comment on whether the company knew who launched the attack. The group is expected to provide more details on August 29 when it announces its second-quarter results.

(Reporting by Matthias Blamont; Editing by Richard Lough, Georgina Prodhan and Jane Merriman)

By Matthias Blamont

Stocks mentioned in the article
ChangeLast1st jan.
BUREAU VERITAS SA 0.19% 21.3 Real-time Quote.19.36%
EUROFINS SCIENTIFIC SE 0.15% 392 Real-time Quote.19.94%
EVOTEC SE -1.50% 18.81 Delayed Quote.9.50%
INTERTEK GROUP -0.05% 5518 Delayed Quote.15.04%
ONE STOP SYSTEMS INC 6.02% 1.76 Delayed Quote.-9.28%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BUREAU VERITAS SA
08/01BUREAU VERITAS : acquires Q Certificazioni and enters the organic food certifica..
07/26MAKO MINING CORP : . - Near Surface, High-grade Gold Intercepted at Las Dolores,..
07/25BUREAU VERITAS : Publication of the half-year financial report for the six month..
07/25BUREAU VERITAS : Strong momentum in the First Half, 2019 outlook confirmed
07/08Eurofins to slow pace of M&A, expand in emerging markets
07/01BUREAU VERITAS : announces divestiture of its North American HSE Consulting busi..
07/01BUREAU VERITAS : Apex Companies, LLC Acquires HSE Consulting Business of Bureau ..
06/27BUREAU VERITAS : Alaro City, Veritas partner on construction quality
06/20BUREAU VERITAS : appoints Industry And Certification director for southern Afric..
06/13BUREAU VERITAS : warns firms to be vigilant
More news
Financials (EUR)
Sales 2019 5 057 M
EBIT 2019 813 M
Net income 2019 393 M
Debt 2019 1 891 M
Yield 2019 2,81%
P/E ratio 2019 23,9x
P/E ratio 2020 21,6x
EV / Sales2019 2,25x
EV / Sales2020 2,10x
Capitalization 9 487 M
Duration : Period :
Bureau Veritas SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BUREAU VERITAS SA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 23,77  €
Last Close Price 21,24  €
Spread / Highest target 22,4%
Spread / Average Target 11,9%
Spread / Lowest Target -5,84%
EPS Revisions
Didier Michaud-Daniel Chief Executive Officer
Aldo Cardoso Chairman
François Chabas Group Chief Financial Officer & Executive VP
Stéphane Bacquaert Director
Pierre Hessler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
EXPERIAN PLC (ADR)--.--%27 733
EDENRED39.43%12 084
INTERTEK GROUP15.04%10 787